FDA gives nod to BrainStorm for ALS trial after Phase III flop

FDA gives nod to BrainStorm for ALS trial after Phase III flop

Source: 
Clinical Trials Arena
snippet: 

BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the US Food and Drug Administration (FDA) following a previous Phase III failure.